UK markets closed

AIM ImmunoTech Inc. (0A4Y.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.4835+0.0335 (+7.44%)
At close: 03:08PM GMT
Full screen
Previous close0.4500
Open0.4734
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.4709 - 0.4835
52-week range0.3797 - 0.7200
Volume4,194
Avg. volume4,764
Market capN/A
Beta (5Y monthly)-0.12
PE ratio (TTM)N/A
EPS (TTM)-0.4040
Earnings date02 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

    Live webcast presentation on Wednesday, April 3rd at 1:35 PM ETOCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York, N.Y., on Wednesday, April 3, 2024, at 1:35 PM ET. In addition to the presentation, management will be available to participate in one-on-one me

  • GlobeNewswire

    AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

    OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the

  • GlobeNewswire

    AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

    Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Erasmus Medical Center Erasmus Medical Center OCALA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the publication of new data analysis from a long-term Early Access Program (“EAP”) studying the company’s drug Ampligen® (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma (“PDAC”). The manuscript